药物信息为HALDOL Decanoate 50 (haloperidol) HALDOL Decanoate 100 (haloperidol) (Ortho-McNeil-Janssen Pharmaceuticals, Inc.): CLINICAL PHARMACOLOGY
- DESCRIPTION
- CLINICAL PHARMACOLOGY
- INDICATIONS AND USAGE
- CONTRAINDICATIONS
- ADVERSE REACTIONS
- OVERDOSAGE
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- PRINCIPAL DISPLAY PANEL - 50 mg/mL label
- PRINCIPAL DISPLAY PANEL- 50 mg/mL box
- 外部链接相关的HALDOL Decanoate 50 (haloperidol) HALDOL Decanoate 100 (haloperidol) (Ortho-McNeil-Janssen Pharmaceuticals, Inc.)
HALDOL Decanoate 50 and HALDOL Decanoate 100 are the long-acting forms of HALDOL (haloperidol). The basic effects of haloperidol decanoate are no different from those of HALDOL with the exception of duration of action. Haloperidol blocks the effects of dopamine and increases its turnover rate; however, the precise mechanism of action is unknown.
Administration of haloperidol decanoate in sesame oil results in slow and sustained release of haloperidol. The plasma concentrations of haloperidol gradually rise, reaching a peak at about 6 days after the injection, and falling thereafter, with an apparent half-life of about 3 weeks. Steady state plasma concentrations are achieved after the third or fourth dose. The relationship between dose of haloperidol decanoate and plasma haloperidol concentration is roughly linear for doses below 450 mg. It should be noted, however, that the pharmacokinetics of haloperidol decanoate following intramuscular injections can be quite variable between subjects.
- Drug Information Provided by National Library of Medicine (NLM).
